Number of HSCT for Autoimmune Diseases: 3789
EBMT Registry – February 2022

Auto-HSCT for AD / Country 1994-2022 (n = 3515) – February 2022

Auto-HSCT for AD: diagnosis per year 1994-2022 (n = 3515) – February 2022

Autoimmune Diseases Working Party

Raffaella Greco, ADWP Chair
Tobias Alexander, ADWP Secretary
Manuela Badoglio, ADWP Study Coordinator

Principal research studies
1. Comparison of CYC+ATG vs. BEAM+ATG conditioning regimens in autologous HSCT for MS
2. NISSC II: Post-AHSCT management and mechanistic immunological reconstitution for patients with systemic sclerosis
3. Late complications after autologous HSCT for Autoimmune Diseases
4. Viral reactivations: retrospective study on viral infections post auto-HSCT in Autoimmune Diseases
5. Indications and outcomes of re-transplantation for Autoimmune Diseases
6. Prospective non-interventional on patients with multiple sclerosis (OMST).

Disease-specific retrospective studies of autologous HSCT
- Immune cytopenias
- Rare neurological diseases (CIDP, Stiff Person Syndrome, myasthenia gravis, NMO and others, juvenile and adult systemic arthritis/Still’s disease
- Polymyositis-Dermatomyositis

Surveys
- Survey of national provision/reimbursement of HSCT and follow up in Autoimmune Diseases

Guidelines and recommendations
- HSCT in adult rheumatological autoimmune diseases: guidelines and recommendations from the EBMT ADWP in collaboration with European Reference Network (ERN) for rare and complex connective tissue diseases (ERN ReCONNET)
- Position paper with European Academy of Neurology EAN/ECTRIMS and EBMT

Prospective long-term follow of studies involving EBMT registry
- Harmanisation of long-term follow-up of clinical trials in MS (EBMT involvement TBC)

Key publications

Major achievements
Over the last 25 years, hematopoietic stem cell transplantation (HSCT) has been increasingly used to treat patients affected by severe and refractory autoimmune diseases (ADs).

The EBMT Autoimmune Diseases Working Party has been central to development of this approach, with over 3,600 HSCT registrations for ADs.

The ADs section of the EBMT Registry is the largest database of its kind worldwide. Recent data have improved the evidence base to support autologous HSCT in multiple sclerosis, systemic sclerosis, and Crohn’s disease, along with a wide range of rarer disease indications, and autologous HSCT has become an integral part of treatment algorithms in various ADs, providing treatment-free remissions by the reinstitution of self-tolerance. A multidisciplinary approach is key in this field, and the ADWP is continuing to expand the evidence-base and support best practice with studies and guidelines, including significant collaborative outputs with other EBMT Working Parties, JACIE, and the EBMT Nurses Group.

Education is central in ADWP activities. A successful and comprehensive ADWP Educational Meeting was held on a virtual platform, due to the ongoing Covid-19 pandemic. Moreover, a section specifically designed for ADs was developed within the EBMT e-learning platform, covering all important aspects of HSCT in relation to the pathophysiology and therapy of ADs, including current and future indications, immunological mechanisms and novel targets.